Literature DB >> 33094358

Allogenic stem cell transplant-associated acute graft versus host disease: a computational drug discovery text mining approach using oral and gut microbiome signatures.

M F Beckman1, D S Morton1, F Bahrani Mougeot2, J-L C Mougeot3.   

Abstract

PURPOSE: Acute graft versus host disease (aGVHD) is a major cause of non-relapse morbidity and mortality post-allogenic hematopoietic stem cell transplant (HSCT). Using conventional literature search and computational approaches, our objective was to identify oral and gut bacterial species associated with aGVHD, potentially affecting drug treatment via lipopolysaccharide (LPS) pathways.
METHODS: Medline, PubMed, PubMed Central, and Google Scholar were searched using MeSH terms. The top 100 hits per database were curated, and 25 research articles were selected to examine oral and gut microbiomes associated with health, HSCT, and aGVHD. Literature search validation, aGVHD drug targets, and microbial metabolic pathway identification were completed using BioReader, MACADAM, KEGG, and STRING programs.
RESULTS: Our review determined that (1) oral genera Rothia, Solobacterium, and Veillonella were identified in HSCT patients' stool and associated with aGVHD; (2) shifts in gut enterococci profiles were determined in HSCT-associated aGVHD; (3) gut microbiome dysbiosis prior or during HSCT and lower Shannon diversity index at time of HSCT were also associated with increased risk of aGVHD and transplant related death; and (4) Coriobacteriaceae family was negatively correlated with gut aGVHD, whereas Eubacterium limosum was associated with decreased risk of chronic GVHD relapse. Additionally, we identified molecular pathways related to TLR4/ LPS, including candidate aGVHD drug targets, impacted by oral and gut bacterial taxa.
CONCLUSION: Reduced microbial diversity reflects higher severity and mortality rate in HSCT patients with aGVHD. Multi-omics approaches to decipher oral and gut microbiome associations will be critical for developing aGVHD preventive therapies.

Entities:  

Keywords:  Acute graft versus host disease; Computational drug discovery; Gut microbiome; Hematopoietic stem cell transplant; Oral microbiome; Text mining

Year:  2020        PMID: 33094358     DOI: 10.1007/s00520-020-05821-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  40 in total

1.  Organ-specific management and supportive care in chronic graft-versus-host disease.

Authors:  Fiona L Dignan; Julia J Scarisbrick; Jacqueline Cornish; Andrew Clark; Persis Amrolia; Graham Jackson; Prem Mahendra; Peter C Taylor; Pallav Shah; Sue Lightman; Farida Fortune; Christopher Kibbler; Jervoise Andreyev; Assunta Albanese; Nedim Hadzic; Michael N Potter; Bronwen E Shaw
Journal:  Br J Haematol       Date:  2012-04-26       Impact factor: 6.998

2.  Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.

Authors:  Frédéric Baron; Rainer Storb; Barry E Storer; Michael B Maris; Dietger Niederwieser; Judith A Shizuru; Thomas R Chauncey; Benedetto Bruno; Stephen J Forman; Peter A McSweeney; Richard T Maziarz; Michael A Pulsipher; Edward D Agura; James Wade; Mohamed Sorror; David G Maloney; Brenda M Sandmaier
Journal:  J Clin Oncol       Date:  2006-08-08       Impact factor: 44.544

3.  Less (bacterial diversity) is more (deaths).

Authors:  John E Levine
Journal:  Blood       Date:  2014-08-14       Impact factor: 22.113

4.  Acute graft-versus-host disease. The incidence and risk factors.

Authors:  Jerzy Wojnar; Sebastian Giebel; Malgorzata Krawczyk-Kulis; Mirosław Markiewicz; Tomasz Kruzel; Iwona Wylezol; Tomasz Czerw; Marek Seweryn; Jerzy Holowiecki
Journal:  Ann Transplant       Date:  2006       Impact factor: 1.530

5.  Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation.

Authors:  Jingbo Yu; Shreekant Parasuraman; Anshul Shah; Daniel Weisdorf
Journal:  Curr Med Res Opin       Date:  2018-12-20       Impact factor: 2.580

6.  Current Use and Trends in Hematopoietic Cell Transplantation in the United States.

Authors:  Anita D'Souza; Stephanie Lee; Xiaochun Zhu; Marcelo Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2017-06-09       Impact factor: 5.742

Review 7.  Pathophysiology of acute graft-versus-host disease: recent advances.

Authors:  Yaping Sun; Isao Tawara; Tomomi Toubai; Pavan Reddy
Journal:  Transl Res       Date:  2007-07-03       Impact factor: 7.012

Review 8.  Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment.

Authors:  Karla Strong Rodrigues; Carla Oliveira-Ribeiro; Silvia de Abreu Fiuza Gomes; Robert Knobler
Journal:  Am J Clin Dermatol       Date:  2018-02       Impact factor: 7.403

Review 9.  Pathophysiology of GvHD and Other HSCT-Related Major Complications.

Authors:  Sakhila Ghimire; Daniela Weber; Emily Mavin; Xiao Nong Wang; Anne Mary Dickinson; Ernst Holler
Journal:  Front Immunol       Date:  2017-03-20       Impact factor: 7.561

Review 10.  Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD.

Authors:  Natalie Köhler; Robert Zeiser
Journal:  Front Immunol       Date:  2019-01-17       Impact factor: 7.561

View more
  4 in total

Review 1.  Acute GVHD: think before you treat.

Authors:  Laura F Newell; Shernan G Holtan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Fecal microbiota transplantation for the treatment of steroid-refractory, intestinal, graft-versus-host disease in a pediatric patient.

Authors:  Pietro Merli; Michele Massa; Alessandra Russo; Francesca Rea; Federica Del Chierico; Federica Galaverna; Francesca Del Bufalo; Stefania Pane; Mattia Algeri; Erminia Francesca Romeo; Luca Masucci; Paola De Angelis; Lorenza Putignani; Franco Locatelli
Journal:  Bone Marrow Transplant       Date:  2022-07-14       Impact factor: 5.174

Review 3.  Osteopontin and Transplantation: Where Are We Now?

Authors:  Beata Kaleta
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-05-21       Impact factor: 4.291

Review 4.  Oral-Gut Microbiome Axis in the Pathogenesis of Cancer Treatment-Induced Oral Mucositis.

Authors:  Ghanyah Al-Qadami; Ysabella Van Sebille; Joanne Bowen; Hannah Wardill
Journal:  Front Oral Health       Date:  2022-03-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.